Remove Gene Editing Remove Genetic Engineering Remove Medicine
article thumbnail

Johns Hopkins Researchers Identify CRISPR Dimmer

The Pharma Data

A naturally occurring system for tuning CRISPR-Cas9 expressing in bacteria, identified in a study published in Cell , could have implications for gene editing therapies as well. In bacteria with unaltered tracr-L, levels of CRISPR-related genes were low. The authors found that tracr-L redirects Cas9 in S.

article thumbnail

Bringing in Light Genome Editing Techniques: ZFN, TALEN and Meganucleases

Roots Analysis

Presently, there are several companies and universities, which are exploring the potential of different gene editing technologies beyond CRISPR for basic research, and the development of gene editing solutions. They also allow genetic material to be added, removed, or altered at particular locations in the genome.

Genome 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Rheumatoid arthritis treated with implanted cells that release drug

The Pharma Data

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically engineered cells that, when implanted in mice, will deliver a biologic drug in response to inflammation.

Drugs 52
article thumbnail

Colorectal Cancer Awareness Month 2024: Innovations in Treatment

XTalks

Gene Editing and CAR T-Cell Therapy Genetic engineering technologies, such as CRISPR-Cas9, are providing newer potential avenues for cancer treatment. For example, gene editing can possibly be used to correct cancer-causing mutations or enhance the effectiveness of chimeric antigen receptor (CAR) T-cell therapy.

article thumbnail

Poseida Joins Roche in $1.5B Deal to Deliver Next-Gen CAR-T Therapies

XTalks

Their pipeline includes P-BCMA-ALLO1, a promising therapy targeting multiple myeloma that has received Regenerative Medicine Advanced Therapy designation and Orphan Drug designation from the US Food and Drug Administration (FDA). Kristin Yarema, President of Cell Therapy at Poseida Therapeutics – Xtalks Life Science Podcast Ep.